Cross-Knorr, Sam <br/><br/>
RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.  [electronic resource] 

 -  BMC cancer  Oct 2013 
 - 463 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-13-463  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacology<br/>Camptothecin--pharmacology<br/>Colonic Neoplasms--genetics<br/>Cytokine Receptor gp130--metabolism<br/>Female<br/>Gene Expression<br/>Humans<br/>Interleukin-6--metabolism<br/>Janus Kinases--metabolism<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Organoplatinum Compounds--pharmacology<br/>Oxaliplatin<br/>Phosphatidylethanolamine Binding Protein--metabolism<br/>Phosphorylation--drug effects<br/>Prognosis<br/>Protein Binding<br/>STAT3 Transcription Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Transcription, Genetic<br/>Tumor Burden